Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH.sub.4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH.sub.4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.

A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.

The present invention relates to the field of vitamin D insufficiency and deficiency, viz. too low blood levels of 25(OH)D, and to their prevention and treatment. It provides a vitamin D supplement which comprises (i) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D2; or (ii) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D3; or (iii) a combination of 25(OH)D3 and/or 25(OH)D2 and a combination of vitamin D2 and vitamin D3, for use in the treatment of and/or prophylaxis of vitamin D insufficiency or deficiency in obese persons, overweight persons having the tendency to get obese or persons having a history of malabsorption of vitamin D or persons with a genetic disposition to develop obesity. Also provided are corresponding compositions and dosage regimens comprising such vitamin D supplements as well as kits comprising such compositions. Furthermore, corresponding dosage regimens for daily administration and corresponding product package inserts are also provided. The invention also relates to corresponding methods of treatment.

The present invention relates to the field of vitamin D insufficiency and deficiency, viz. too low blood levels of 25(OH)D, and to their prevention and treatment. It provides a vitamin D supplement which comprises (i) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D2; or (ii) a combination of 25(OH)D3 and/or 25(OH)D2 and vitamin D3; or (iii) a combination of 25(OH)D3 and/or 25(OH)D2 and a combination of vitamin D2 and vitamin D3, for use in the treatment of and/or prophylaxis of vitamin D insufficiency or deficiency in obese persons, overweight persons having the tendency to get obese or persons having a history of malabsorption of vitamin D or persons with a genetic disposition to develop obesity. Also provided are corresponding compositions and dosage regimens comprising such vitamin D supplements as well as kits comprising such compositions. Furthermore, corresponding dosage regimens for daily administration and corresponding product package inserts are also provided. The invention also relates to corresponding methods of treatment.

A composition for oral administration to a periparturient mammal at risk of developing hypocalcemia within 0-6 hours after parturition; the composition comprising a form of calcium rapidly absorbable by the periparturient mammal using passive paracellular transport across the intestinal epithelium and a 1-alpha hydroxylated vitamin D compound in an amount sufficient to stimulate active transport of calcium across the intestinal epithelium, the calcium and the 1-alpha hydroxylated vitamin D being administered concurrently to support maintenance of normal blood calcium concentrations in the periparturient mammal.